"Having control over our own supply chain will greatly increase
our efficiencies, including the time and cost required to have
processed product readily available for development into all our
formulations. We will soon launch our observational studies for
specific cannabinoid combinations targeting critical ailments. We
will be growing a variety of cannabinoid combinations for our
formulations and testing. Each formulation is designed to target a
specific critical ailment; to work using a particular delivery
mode; and to have the potency to drive maximum positive results in
patient usage," stated CMO Dr. Allen Herman.
CBIS, Inc. has received several hundred emails inquiring about
the timing of clinical research and the availability of treatment
options. These inquiries cover the management of pain, peripheral
neuropathies, cancer, and COPD. All inquiries are entered into our
in-house database and we will be responding to each person as each
targeted observational study officially commences. The studies will
include some of the over 500 cannabinoids that have been isolated
and identified from Cannabis sativa. The cannabinoids belong to the
chemical class of terpenophenolics, of which 85 have been uniquely
identified in cannabis. Common plant cannabinoids
(phytocannabinoids) include: tetrahydrocannabinol (THC),
cannabidiol (CBD), cannabigerol (CBG), cannabichromene (CBC), and
cannabinol (CBN). The pharmacology of THC has been widely studied,
and it is regarded as the main psychoactive constituent of
cannabis. Our in-house database will form the basis of
patient-centered outcomes research (PCOR) for a variety of critical
conditions.
CBIS will then develop protocols for our international
consortium of US, South African, and European universities and
research institutions. This consortium will develop research
protocols for animal studies and clinical trials for several
critical clinical ailments concurrently. The Cannabis Science
Research Laboratory will have principal investigators at each
partner institution and will work closely with CBIS leadership. Our
initial animal studies will focus on cancers, and our clinical
trials will concentrate on Cancers, PTSD, pain management,
HIV/AIDS, and neurological conditions including sleep disorders.
CBIS will then add other targeted ailments for clinical trials as
the demand and need is identified in each jurisdiction. Each
country that we collaborate in will ensure that the research is
done within the approval guidelines for that country and follows
the approval guidelines for the US Food and Drug Administration
providing nationwide federal government approvals.
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique
understanding of metabolic processes to provide novel treatment
approaches to a number of illnesses for which current treatments
and understanding remain unsatisfactory. Cannabinoids have an
extensive history dating back thousands of years, and currently,
there are a growing number of peer-reviewed scientific publications
that document the underlying biochemical pathways that cannabinoids
modulate. The Company works with leading experts in drug
development, medicinal characterization, and clinical research to
develop, produce, and commercialize novel therapeutic approaches
for the treatment for illnesses caused by infections as well as for
age-related illness. Our initial focus is on skin cancers,
HIV/AIDS, and neurological conditions. The Company is proceeding
with the research and development of its proprietary drugs as a
part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1,
respectively.
Forward-Looking Statements
This Press Release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Act of 1934. A statement containing
words such as "anticipate," "seek," intend," "believe," "estimate,"
"expect," "project," "plan," or similar phrases may be deemed
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Some or all of the events
or results anticipated by these forward-looking statements may not
occur. Factors that could cause or contribute to such differences
include the future U.S. and global economies, the impact of
competition, and the Company's reliance on existing regulations
regarding the use and development of cannabis-based drugs. Cannabis
Science, Inc. does not undertake any duty nor does it intend to
update the results of these forward-looking statements. Safe Harbor
Statement. The Private Securities Litigation Reform Act of 1995
provides a 'safe harbor' for forward-looking statements. Certain of
the statements contained herein, which are not historical facts are
forward looking statements with respect to events, the occurrence
of which involved risks and uncertainties. These forward-looking
statements may be impacted, either positively or negatively, by
various factors. Information concerning potential factors that
could affect the company is detailed from time to time in the
company's reports filed with the Securities and Exchange
Commission.